BRIEF—Early data spur Hummingbird to license cancer candidate

Singaporean biotech Hummingbird Bioscience has exercised an option to license a new HER3-targeted antibody from Cancer Research Horizons, the innovation arm of Cancer Research UK.

The move comes after positive data emerged from a Phase Ia trial of HMBD-001, a differentiated and potentially best-in-class candidate for solid tumors.

Chief executive Piers Ingram said: “We look forward to accelerating the opening of multiple Hummingbird-sponsored Phase Ib/II studies.”

The firm plans multiple studies in biomarker-selected populations during the second half of 2023, while Cancer Research will continue its work, leading to a dose expansion study in prostate cancer later this year.